Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy

被引：0
|
作者：
James W. Wheless
Dennis Dlugos
Ian Miller
D. Alexander Oh
Neha Parikh
Steven Phillips
J. Ben Renfroe
Colin M. Roberts
Isra Saeed
Steven P. Sparagana
Jin Yu
Maria Roberta Cilio
机构：
[1] University of Tennessee Health Science Center,Doernbecher Childhood Epilepsy Program, Department of Pediatrics
[2] Le Bonheur Children’s Hospital,UCSF Benioff Children’s Hospital
[3] Children’s Hospital of Philadelphia,Saint
[4] Perelman School of Medicine at the University of Pennsylvania,Luc University Hospital
[5] Nicklaus Children’s Hospital,undefined
[6] INSYS Development Company,undefined
[7] Inc.,undefined
[8] Mary Bridge Children’s Neurology Clinic,undefined
[9] Child Neurology Center of Northwest Florida,undefined
[10] Oregon Health and Science University,undefined
[11] University of California San Francisco,undefined
[12] Texas Scottish Rite Hospital for Children,undefined
[13] University of Louvain,undefined
[14] Arena Pharmaceuticals,undefined
来源：
CNS Drugs | 2019年 / 33卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：593 / 604
页数：11
相关论文
共 27 条
  • [21] Efficacy and tolerability of levetiracetam during one-year follow-up as add-on therapy in patients with treatment-resistant epilepsy\
    Kkolou, E.
    Dietis, A.
    Flourentzou, A.
    Malikkidou, A.
    Petsa, M.
    Stylianidou, G.
    Papacostas, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 217 - 217
  • [22] Efficacy and tolerability of oxcarbazepine during one-year follow-up as add-on therapy in patients with treatment-resistant epilepsy
    Kkolou, E.
    Kleopa, K.
    Papacostas, S.
    EPILEPSIA, 2006, 47 : 145 - 145
  • [23] Efficacy and tolerability of levetiracetam during one-year follow-up as add-on therapy in patients with treatment-resistant generalised epilepsy
    Kkolou, E.
    Flourentzou, A.
    Malikkidou, A.
    Stylianidou, G.
    Papacostas, S.
    JOURNAL OF NEUROLOGY, 2007, 254 : 50 - 50
  • [24] First-In-Human Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of AZP2006, A Synthetic Compound for the Treatment of Alzheimer's Disease and Related Diseases
    Verwaerde, Philippe
    Estrella, Cecilia
    Burlet, Stephane
    Barrier, Mathieu
    Marotte, Andree-Anne
    Clincke, Gilbert
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 98 (02) : 715 - 727
  • [25] Challenges Associated With Enrolling Pediatric Patients With Treatment-Resistant Epilepsy Aged 25 Years in a Clinical Trial and Lessons Learned for Future Trials
    Segal, E. B.
    Wheless, J. W.
    Zafar, M.
    Shih, E.
    Ngo, L.
    Rabinowicz, A.
    Carrazana, E.
    ANNALS OF NEUROLOGY, 2025, 96 : S45 - S45
  • [26] Safety, Tolerability, and Pharmacokinetics of a Novel Synthetic Disease Modifying Antirheumatic Drug, TCK-276, After Single Ascending Dose in Healthy Subjects and Multiple Ascending Doses in Patients with Rheumatoid Arthritis
    Watai, Chie
    Tsuruda, Kazuoki
    Tsumura, Yoshinori
    Tasaki, Daisuke
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 862 - 863
  • [27] A randomized, double-blind, placebo-controlled, dose-escalating phase IIa trial to evaluate the safety, tolerability, efficacy, and pharmacokinetics of multiple oral doses of Pynegabine tablets as add-on therapy in patients with focal epilepsy
    Wei, Shan
    Shiwen, Weng
    Cao-wenjing, Chang
    Huajun, Yang
    Qun, Wang
    CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (09)
123